Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01534624
Other study ID # 999912476
Secondary ID 12-DA-N476
Status Completed
Phase
First received
Last updated
Start date February 7, 2012
Est. completion date July 30, 2014

Study information

Verified date July 30, 2014
Source National Institutes of Health Clinical Center (CC)
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Background:

- Researchers are interested in studying the roles that genes play in drug and alcohol addiction. Genes seem to account for about half of the differences between people who become addicted to drugs and people who do not. This study will collect blood and skin cell samples. These cells will be used to develop stem cells that are useful for studying how genes are related to drug use and dependence.

Objectives:

- To study genetic and cellular differences between people who are addicted to drugs and those who are not.

Eligibility:

- Individuals between 21 and 65 years of age who do not use drugs.

- Individuals between 21 and 65 years of age who are in treatment with buprenorphine or methadone.

Design:

- Participants will be screened with a brief physical exam and medical history.

- Participants will also answer questions about physical and mental health, quality of life, and history of drug and alcohol use. A urine sample and cheek swab sample will be collected.

- Participants whose genetic samples match the study requirements will be asked to come back to provide a skin biopsy sample and a second urine sample.


Description:

Background - The molecular- and cellular-based mechanisms that contribute to the initiation and development of addiction remain to be elucidated. Estimates have suggested that 40-60 percent of the vulnerability to addiction may be attributable to genetic aberrations. Multiple chromosomal regions have been linked to addiction including those containing the dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) genes. Current efforts to understand how polymorphisms in these monoamine transporters contribute to the molecular mechanisms of addiction are severely hindered by the inability to directly interrogate neural cell types from the patients. There is great potential for patient-specific iPS cell technology to profoundly impact our understanding of human development and disease by providing genetically distinct, functional sources of human cells.

Objective - The objective of the research is to develop a cell-based system whereby neural cells from afflicted individuals can be functionally assayed to interrogate the molecular mechanisms underlying addiction.

Study population Controls (non-drug users) and opioid dependent adults receiving opioid agonist therapy aged 21- 65 will be enrolled.

Design Participants demographic characteristics, psychosocial evaluation, and psychiatric, medical, and drug use histories will be characterized. DNA will be collected via cheek swabs of up to 30 potential participants for determination of dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) gene polymorphisms. Participants (N=16) with suitable polymorphisms will be asked to under go skin biopsies; 2 individuals for each of two genotypes for each gene (DAT or VMAT), i.e., 8 samples from addicts and 8 samples for control subjects. Collaborators at Case Western Reserve University will use the skin cells to derive and characterize patient-specific, induced pluripotent stem (iPS) cells that carry monoamine transporter polymorphisms for the hDAT1 and hVMAT2 genes. They will differentiate patient-specific iPS cells line into dopaminergic neurons and carry out a detailed and functional characterization of these cells to identify their molecular characteristics.

Outcome measures - Biological specimens from the addiction patients and controls will be used to derive and characterize patient-specific, induced pluripotent stem (iPS) cells that carry monoamine transporter polymorphisms. Patient-specific iPS cells lines will be differentiated into dopaminergic neurons. In follow up studies, we will characterize, compare, and functionally assay these patient-specific, iPS cell-derived dopaminergic neurons from control and addiction patients that carry polymorphisms for hDAT1 and hVMAT2 gene to investigate any possible association with dopamine neurotransmission variations and vulnerability to addiction.


Recruitment information / eligibility

Status Completed
Enrollment 49
Est. completion date July 30, 2014
Est. primary completion date
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 21 Years to 65 Years
Eligibility - INCLUSION CRITERIA:

1. 21 to 65 years old

Opioid dependent participant group only:

2. enrollment in a substance abuse treatment protocol in Archway.

Non-drug users

3. no lifetime history of drug dependence as indicated by the screening ASI and Substance Abuse/Dependence Evaluation counselor interview.

EXCLUSION CRITERIA:

1. Relevant neurological disorders (including, but not limited to, Parkinson s disease and Huntington s disease).

2. contraindications to skin biopsy including, but not limited to, bleeding disorders, skin disorders, and immune disorders, that the MAI determines may alter the risk of the biopsy.

3. cognitive impairment severe enough to preclude informed consent or valid responses on questionnaires.

4. controls will also be excluded if they test positive for drugs or alcohol during screening or study visits.

5. unwillingness to allow samples to be kept for future research.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States National Institute on Drug Abuse Baltimore Maryland

Sponsors (1)

Lead Sponsor Collaborator
National Institute on Drug Abuse (NIDA)

Country where clinical trial is conducted

United States, 

References & Publications (3)

Hyman SE, Malenka RC. Addiction and the brain: the neurobiology of compulsion and its persistence. Nat Rev Neurosci. 2001 Oct;2(10):695-703. Review. — View Citation

Nestler EJ. Molecular basis of long-term plasticity underlying addiction. Nat Rev Neurosci. 2001 Feb;2(2):119-28. Review. Erratum in: Nat Rev Neurosci 2001 Mar;2(3):215. — View Citation

Wise RA, Bozarth MA. A psychomotor stimulant theory of addiction. Psychol Rev. 1987 Oct;94(4):469-92. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Derive and characterize patient-specific, induced pluripotent stem (iPS) cells that carry monoamine transporter polymorphisms and differentiate them into dopaminergic neurons.
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05214742 - Developing Derived Induced Pluripotent Stem Cells as a Model to Understand Imprinted Disorders
Withdrawn NCT02056613 - Blood Collection From Healthy Volunteers and Patients for the Production of Clinical Grade Induced Pluripotent Stem Cell (iPSC) Products
Recruiting NCT01454765 - Generation of Haploid Stem Cells From Human Germ Cells N/A